

# Mohammed Alshalalfa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1631465/publications.pdf>

Version: 2024-02-01

29  
papers

1,629  
citations

471509

17  
h-index

501196

28  
g-index

29  
all docs

29  
docs citations

29  
times ranked

2683  
citing authors

#	ARTICLE	IF	CITATIONS
1	Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 309-316.	3.9	8
2	Clinicogenomic characterization of prostate cancer liver metastases. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 366-369.	3.9	7
3	Racial Differences in Genomic Profiles of Breast Cancer. <i>JAMA Network Open</i> , 2022, 5, e220573.	5.9	11
4	The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair. <i>Nature Communications</i> , 2021, 12, 401.	12.8	60
5	Correlative analysis between two commercially available post-prostatectomy genomic tests. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 575-577.	3.9	0
6	Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. <i>Communications Biology</i> , 2021, 4, 670.	4.4	50
7	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , 2021, 79, 717-721.	1.9	13
8	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). <i>Cancer Genetics</i> , 2021, 258-259, 61-68.	0.4	2
9	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 7349.	12.8	51
10	Genomic and clinical characterization of stromal infiltration markers in prostate cancer. <i>Cancer</i> , 2020, 126, 1407-1412.	4.1	8
11	A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. <i>Nature Cancer</i> , 2020, 1, 1082-1096.	13.2	49
12	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.	21.4	198
13	Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 19, 246-254.e5.	1.9	9
14	Racial Differences in Genomic Profiling of Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1083-1085.	27.0	87
15	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. <i>Nature Communications</i> , 2020, 11, 5549.	12.8	76
16	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020, 78, 327-332.	1.9	18
17	Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 936-940.	0.8	3
18	Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 3453-3461.	5.1	18

#	ARTICLE	IF	CITATIONS
19	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Na <sup>+</sup> -ve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6721-6730.	7.0	74
20	Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. <i>European Urology Oncology</i> , 2019, 2, 405-412.	5.4	14
21	The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. <i>European Urology</i> , 2018, 74, 444-452.	1.9	55
22	The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. <i>GigaScience</i> , 2018, 7, .	6.4	54
23	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 1663.	7.1	219
24	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. <i>Clinical Cancer Research</i> , 2017, 23, 7072-7083.	7.0	87
25	Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. <i>BMC Cancer</i> , 2017, 17, 759.	2.6	57
26	SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. <i>Journal of Urology</i> , 2016, 196, 1436-1444.	0.4	38
27	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1612-1620.	10.7	182
28	Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. <i>European Urology</i> , 2015, 68, 555-567.	1.9	125
29	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. <i>Clinical Cancer Research</i> , 2015, 21, 5619-5629.	7.0	56